⏳ Fetching live dividend data...
Home › Calculator › SUPN Dividend Calculator 2026
Supernus Pharmaceuticals, Inc. · NASDAQ
Price: $44.89 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SUPN → $144.7K in 10 years · $42.60/month
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SUPN position with:
Real after-tax yield depends on where you live and how you hold SUPN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.46% | 1.66% | $446 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.79% | 0.99% | $379 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.57% | 0.77% | $357 / yr |
| 🇬🇧 UK ISA | 0% | 4.46% | 1.66% | $446 / yr |
| 🇬🇧 UK Taxable | 8.75% | 4.07% | 1.27% | $407 / yr |
| 🇨🇦 TFSA | 0% | 4.46% | 1.66% | $446 / yr |
| 🇨🇦 CA Taxable | 25% | 3.34% | 0.54% | $335 / yr |
| 🇦🇺 Super (pension) | 15% | 3.79% | 0.99% | $379 / yr |
| 🇦🇺 AU Taxable | 30% | 3.12% | 0.32% | $312 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.28% | 0.48% | $328 / yr |
| 🇫🇷 FR Taxable | 30% | 3.12% | 0.32% | $312 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SUPN pays quarterly — 4 times per year. Next ex-div: TBD.
How SUPN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SUPN sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-03-16 | 5,000 | $27.94 | $139.7K | ||
| M-Exempt | 2026-03-17 | 15,000 | $38.60 | $579.0K | ||
| M-Exempt | 2026-03-16 | 18,000 | $32.20 | $579.6K | ||
| M-Exempt | 2026-03-17 | 12,250 | $36.75 | $450.2K | ||
| M-Exempt | 2026-03-16 | 4,250 | $29.61 | $125.8K | ||
| M-Exempt | 2026-03-16 | 22,750 | $36.75 | $836.1K | ||
| M-Exempt | 2026-03-17 | 22,750 | $39.40 | $896.4K | ||
| Sale | 2026-03-17 | 27,710 | $49.95 | $1.38M | ||
| Sale | 2026-03-16 | 34,114 | $50.18 | $1.71M | ||
| M-Exempt | 2026-03-18 | 7,250 | $39.40 | $285.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SUPN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →